Scientists have failed to show that weight-loss wonder drug semaglutide slows the progress of Alzheimer’s disease (AD), as two-year clinical trials end in disappointment for

In a study led by researchers at Mass General Brigham, pregnant individuals who stopped taking popular weight loss GLP-1 medications before or early in their

A new study hints that pregnant people who have previously taken drugs like Ozempic may face a higher risk of certain poor pregnancy outcomes. But

Ozempic Drug Fails to Quell Alzheimer’s in Novo Nordisk Trials  The New York Times Semaglutide fails to slow progression of Alzheimer’s in highly anticipated trials, Novo

PHOTO ART: MERCA2.0 The Economist published its traditional end-of-year special edition, The World Ahead 2026, an in-depth analysis projecting the key themes and trends that

The studies were a significant setback for the optimistic view that semaglutide and other GLP-1 drugs could help prevent a number of brain diseases.

The studies may still hold clues to the powers and limits of GLP-1 drugs

The complicated relationship between GLP-1s and pregnancy  The Washington Post Patients who discontinue GLP-1s found to have more weight gain, complications during pregnancy  Medical Xpress New Moms’

Can GLP-1s treat vascular dementia? One study failed, but some researchers are holding out hope.

(MedPage Today) — The oral GLP-1 receptor agonist semaglutide (Rybelsus) did not slow Alzheimer’s disease progression in the highly awaited EVOKE phase III trials, Novo

We knew the weight would return, but what happens to the other benefits when patients are no longer taking GLP-1 drugs? Medscape

(MedPage Today) — The recommended discontinuation of GLP-1 receptor agonists during pregnancy was associated with more gestational weight gain and higher risks of pregnancy complications,

Researchers say a woman struggling with obesity who couldn’t resist eating fatty foods experienced declines in her cravings after taking tirzepatide.

Top-line results from two large clinical trials by Novo Nordisk, the company behind Ozempic and Wegovy, found oral semaglutide failed to slow down Alzheimer’s progression

This paper advances a metabolic hypothesis that I certainly didn’t see coming. One of the great mysteries about alcoholism/alcohol use disorder is its underlying biochemical

GLP-1s are helping Americans live better, but Washington has major work to do on safety. A lot has been happening this fall with the rocket ship rise

Drug maker Novo Nordisk says semaglutide, the active ingredient for the weight loss jab Wegovy, does not slow Alzheimer’s — despite initial hopes that it

(MedPage Today) — Prescriptions for GLP-1 receptor agonists increased among postpartum women once semaglutide (Ozempic, Wegovy) was approved for weight loss, a Danish epidemiological study

Seamus Fernandez, Guggenheim biotech analyst, joins ‘Power Lunch’ to discuss Novo Nordisk’s latest earnings results, if there’s a clear winner in the GLP-1 space and

In a study led by researchers at Mass General Brigham, pregnant individuals who stopped taking popular weight loss GLP-1 medications before or early in their

Many people using GLP-1 weight loss drugs are seeing big changes during the holiday season. These medicines make people feel full faster, so Thanksgiving meals

Key Points Eli Lilly has a dominant share of the huge and expanding GLP-1 drug market. Its GLP-1 drugs will soon be partially covered by

Strategy Investor behavior matters a lot when it comes to investing in ‘oddball funds.’ (morningstar.com) Bubbles are only obvious in hindsight. (ritholtz.com) Crypto How the

Two major clinical trials evaluating the potential of the weight-loss drug semaglutide to treat Alzheimer’s disease have concluded without showing the desired clinical benefit. The

The use of glucagon-like peptide (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists, such as tirzepatide, continues to climb amidst patient demand and a growing

The studies offer perhaps the most concrete rebuttal yet to an idea that GLP-1 drugs, which have profound benefits on weight loss and heart health, might

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as liraglutide and semaglutide, have revolutionized treatment of obesity. Obesity and obesity-related comorbidities increase the risks of adverse outcomes

This study uses data from the Danish Medical Birth Register to examine postpartum use of glucagon-like peptide 1 receptor agonists.

This cohort study examines gestational weight gain and pregnancy outcomes after glucagon-like peptide-1 (GLP-1) receptor agonist discontinuation.

Telehealth companies are promoting GLP-1 medications such as Ozempic and Wegovy for cosmetic weight loss in non-obese patients, despite FDA limitations on their approved use,

Last week, Novo Nordisk NVO announced that its popular semaglutide-based GLP-1 injections, Wegovy (for obesity) and Ozempic (for diabetes), will be offered at a limited-time

Indianapolis-based Eli Lilly is the first publicly traded U.S. healthcare company to reach market capitalization over $1 trillion, elevating the drugmaker to an exclusive list

Data provides new insights into targeting the diverse pathobiology of Alzheimer’s disease, an approach spearheaded by the ADDF NEW YORK, Nov. 24, 2025 /PRNewswire/ —

Novo Nordisk Shares Slump After Ozempic Pill Fails in Alzheimer’s Trials  The Wall Street JournalView Full Coverage on Google News

When women taking weight loss jabs stop their use because of pregnancy, the rebound weight gain brings health risks for their babies. Women who paused

FAT jabs could harm mum and baby if taken too close to pregnancy, a study suggests. Women who used the GLP-1 injections, such as Wegovy

An oral version of the GLP-1 drug semaglutide failed to significantly slow the disease’s progression compared to a placebo.

A new study sheds light on the risks and benefits of taking GLP-1 weight-loss drugs before having a baby.